Zobrazeno 1 - 10
of 23
pro vyhledávání: ''
Autor:
J. Jack Lee, Bettzy Stephen, Vivek Subbiah, Vincent A. Miller, Yali Li, Siqing Fu, Ralph Zinner, Sarina Anne Piha-Paul, Roosevelt Anderson, Apostolia Maria Tsimberidou, Danxia Ke, Jennifer J. Wheler, Razelle Kurzrock, Gerald Steven Falchook, Aung Naing, Daniel D. Karp, Filip Janku, David S. Hong, Roman Yelensky
Publikováno v:
Cancer Research. 76:3690-3701
Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve a major challenge for early-phase clinical trials, which is to recruit patients who, while
Autor:
Michael J. Silverberg, Elizabeth L. Yanik, Hormuzd A. Katki, Eric A. Engels, M. Michele Manos, Anil K. Chaturvedi
Publikováno v:
Cancer Prevention Research. 8:857-863
Screening for oral leukoplakia, an oral cavity cancer (OCC) precursor, could lead to earlier detection of OCC. However, the progression rate from leukoplakia to OCC and the benefits of leukoplakia screening for improving OCC outcomes are currently un
Autor:
Susan Moran, Shih Yuan Lee, Hans J. Hammers, H. Mark Lin, Charles J. Ryan, Paul G. Corn, Maha Hussain, Justine Yang Bruce, Joshi J. Alumkal, Daniel J. George, M. Dror Michaelson
Publikováno v:
Clinical Cancer Research. 20:4218-4227
Purpose: Orteronel (TAK-700) is an investigational, nonsteroidal, oral, inhibitor of androgen synthesis with greater specificity for 17,20-lyase than for 17α-hydroxylase. We investigated orteronel without steroids in patients with nonmetastatic cast
Autor:
J. Marc Pipas, Murray B. Resnick, Guillaume Beaudry, Umar Farooq, Udo Kellner, David G. Huntsman, Christophe Louvet, Richard B. Everson, Emily S. Pavey, Thomas E. Clancy, Tsung Teh Wu, Michael O. Meyers, Yves Fradet, Sharlene Gill, Qian Shi, Daniel J. Sargent, Jean Francois Haince, Pierre Validire
Publikováno v:
Clinical Cancer Research. 20:4361-4369
Purpose: Recurrence risk assessment to make treatment decisions for early-stage colon cancer patients is a major unmet medical need. The aim of this retrospective multicenter study was to evaluate the clinical utility of guanylyl cyclase C (GCC) mRNA
Publikováno v:
Cancer Prevention Research. 5:874-882
Objective is to predict smoking attributable deaths (SAD) for lung cancer and all causes in Italy, 2015 to 2040, assuming a yet unimplemented tobacco control policies (TCP) and a national, low-dose, lung cancer, computed tomography (CT) annual screen
Autor:
Paul Frankel, John M. Kirkwood, Janice Shipe-Spotloe, David R. Gandara, Alice P. Chen, Kim Margolin, Scott D Christensen, Christopher Ruel, Ahmad A. Tarhini
Publikováno v:
Clinical Cancer Research. 17:6574-6581
Purpose: Aflibercept is a soluble decoy VEGF receptor and angiogenesis inhibitor with potent preclinical antitumor activity in melanoma. We conducted a multicenter phase II study in patients with inoperable stage III or IV melanoma and no prior chemo
Publikováno v:
Clinical Cancer Research. 17:5205-5214
Purpose: Platinum-based doublets are the cornerstone of treatment in advanced non–small-cell lung cancer (NSCLC) and often include vinorelbine or taxanes. A predictive biomarker is greatly needed to select chemotherapy-sensitive patients for these
Autor:
Stuart A. Grossman, Steven Piantadosi, Serena Desideri, Joy D. Fisher, Xiaobu Ye, Louis B. Nabors, Myrna R. Rosenfeld
Publikováno v:
Grossman, SA; Ye, X; Piantadosi, S; Desideri, S; Nabors, LB; Rosenfeld, M; et al.(2010). Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clinical Cancer Research, 16(8), 2443-2449. doi: 10.1158/1078-0432.CCR-09-3106. UCLA: Retrieved from: http://www.escholarship.org/uc/item/2rc9w0tx
Purpose: Novel agents are currently combined with radiation and temozolomide (RT + TMZ) in newly diagnosed glioblastoma using overall survival as the primary end point. Results of these phase II studies are typically compared with the phase III Europ
Autor:
Timothy G. Larson, Vincent A. Miller, Lyudmila Bazhenova, Roger B. Cohen, Philip J. Stella, Shirish M. Gadgeel, Paulina Selaru, Eric B. Haura, Peter D. Eisenberg, Keith D. Wilner, Alejandro D. Ricart
Publikováno v:
Clinical Cancer Research. 16:2450-2457
Purpose: To evaluate the efficacy of mitogen-activated protein kinase/extracellular signal-related kinase kinase inhibitor PD-0325901 in advanced non–small cell lung cancer patients who had experienced treatment failure after, or were refractory to
Autor:
John R. Murren, William J. Hicks, Gregory A. Otterson, Miguel A. Villalona-Calero, Scott N. Gettinger, John A. Ellerton, Xueliang Pan
Publikováno v:
Clinical Cancer Research. 16:2466-2473
Purpose: We have shown the feasibility of administering inhaled doxorubicin to patients with cancer. This study evaluated inhaled doxorubicin combined with cisplatin and docetaxel in patients with non–small cell lung cancer. The principal objective